FilingReader Intelligence
Dr. Reddy's reports 11% revenue growth to $997m
July 29, 2025 at 05:49 PM UTC•By FilingReader AI
Dr. Reddy's Laboratories reported Q1 FY26 revenues of ₹8,545 crores ($997 million), up 11% year-over-year, with strong performance across most markets except US generics.
EBITDA reached ₹2,278 crores ($266 million) with a 26.7% margin. The company holds a net cash surplus of $341 million and expects Semaglutide approval and launch in early 2026.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:DRREDDY•Bombay Stock Exchange
News Alerts
Get instant email alerts when Dr. Reddy's Laboratories publishes news
Free account required • Unsubscribe anytime